FILTER

FILTERED INTERVIEW RESULTS

Sergio Aburto

DIRECTOR LATIN AMERICA NORTH, ACADIAN PLANT HEALTH
"We harvest our Ascophyllum nodosum manually to maintain the seaweed beds, as machine-harvesting may damage the seaweed."

Sergio Chiñas

CEO, FIRST QUALITY CHEMICALS
"I want to preserve the fantastic work culture that we have built here over the years. Keeping this culture intact would be our priority in any M&A deal."

Rafael Méndez

VICE PRESIDENT, CRODA LATAM
"Mexico as a country has a very matured and experienced manufacturing industry and has the right competitive advantages to become the first supplier for various markets in the US."

Alejandro Iniestra

GENERAL MANAGER, KIGO CHEMICAL
"Our investment in digital capabilities has proven pivotal. KigoConnect, our customer access platform, has seen substantial growth."

Luis Osorio

EXECUTIVE DIRECTOR, PROCCYT
"Due to the regulatory backlog of approval, innovation in Mexico has paused in the past five years."

Miguel Valdivia

COMMERCIAL DIRECTOR, TRADE CHEMICALS & PRODUCTS
"Mexico is full of opportunities—there are always new factories and new clients."

Javier Constante

PRESIDENT, DOW LATIN AMERICA
"Our LatAm portfolio reflects Dow’s global capabilities, with more than 50% focused on specialty plastics for the packaging industry."

Flor de María González

GENERAL MANAGER, ANAFAPYT
"We will continue supporting sustainable raw materials production and the development of new alternatives."

Alfredo Ison

PRESIDENT, QUÍMICA DELTA
"In the past, we diversified into the fuel market with a company called Exxia. Today, we have the new specialties company, Ion."

Jody Kuzenko

PRESIDENT AND CEO, TOREX GOLD RESOURCES
"With US$508 million left to spend on the Media Luna project south of the river, we have a strong, cash-producing asset at ELG that is financing the construction of our future."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS